{'fraction_non_alphanumeric': 0.016260162601626018, 'fraction_numerical': 0.0, 'mean_word_length': 5.099009900990099, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A brighter future for melanoma

Ipilimumab does carry a survival advantage in the adjuvant setting but was considered too toxic for routine use. Other adjuvant studies have demonstrated benefits in terms of recurrence-free survival, but are not yet sufficiently mature to demonstrate an advantage in terms of overall survival. As the editorial contends, it is likely that disease-free survival will be followed by an improvement in overall survival, particularly as nivolumab is already known to be more effective than ipilimumab in the adjuvant setting. This article is protected by copyright. All rights reserved.